Cell-free DNA-guided detection, surveillance, and therapeutic adaptation for breast cancer

Plasma cell-free DNA (cfDNA) analysis provides a minimally invasive approach to breast cancer assessment across early detection, minimal residual disease (MRD) monitoring, and treatment adaptation in advanced disease. This review evaluates these applications by distinguishing analytical validity, clinical detection performance, prognostic validity, and clinical utility. In early detection, assays integrating genomic, epigenomic, fragmentomic, and protein-based features have shown encouraging performance in evaluated cohorts; however, sensitivity remains limited in low-burden disease, particularly stage I breast cancer. Their potential clinical role depends on the incremental information they provide beyond established imaging and diagnostic pathways. In the curative-intent setting, circulating tumor DNA detection after treatment is associated with recurrence risk and can precede clinical or radiographic relapse, supporting prognostic stratification and the design of MRD-guided intervention trials. Whether such interventions improve clinical outcomes remains a central unresolved question. In advanced breast cancer, plasma genotyping supports treatment selection in defined molecular contexts. Randomized trials of ESR1 mutation-guided endocrine switching have demonstrated progression-free survival benefits with specific treatment strategies, providing evidence beyond biomarker-outcome associations, although overall survival benefit remains to be established. Across applications, interpretation depends on assay characteristics, molecular input, disease setting, sampling schedule, and the clinical decision being evaluated. Future studies should connect assay performance to patient benefit through comparison with existing care, clinically meaningful endpoints, and assessment of treatment burden and downstream investigations. This approach will help define where cfDNA testing can contribute meaningfully to breast cancer management.

Authors

Institutions

Publication Details

Journal
Biomarker Research
Published
2026-11-19
DOI
https://doi.org/10.1186/s40364-026-01048-1
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cell-free DNA-guided detection, surveillance, and therapeutic adaptation for breast cancer

Tsun Wai Chow, Ava Kwong, Sze Keong Tey, Chengxin Li
Biomarker Research
Cancer Genomics and Diagnostics
article

Cell-free DNA-guided detection, surveillance, and therapeutic adaptation for breast cancer

Tsun Wai Chow, Ava Kwong, Sze Keong Tey, Chengxin Li
article en

Abstract

Plasma cell-free DNA (cfDNA) analysis provides a minimally invasive approach to breast cancer assessment across early detection, minimal residual disease (MRD) monitoring, and treatment adaptation in advanced disease. This review evaluates these applications by distinguishing analytical validity, clinical detection performance, prognostic validity, and clinical utility. In early detection, assays integrating genomic, epigenomic, fragmentomic, and protein-based features have shown encouraging performance in evaluated cohorts; however, sensitivity remains limited in low-burden disease, particularly stage I breast cancer. Their potential clinical role depends on the incremental information they provide beyond established imaging and diagnostic pathways. In the curative-intent setting, circulating tumor DNA detection after treatment is associated with recurrence risk and can precede clinical or radiographic relapse, supporting prognostic stratification and the design of MRD-guided intervention trials. Whether such interventions improve clinical outcomes remains a central unresolved question. In advanced breast cancer, plasma genotyping supports treatment selection in defined molecular contexts. Randomized trials of ESR1 mutation-guided endocrine switching have demonstrated progression-free survival benefits with specific treatment strategies, providing evidence beyond biomarker-outcome associations, although overall survival benefit remains to be established. Across applications, interpretation depends on assay characteristics, molecular input, disease setting, sampling schedule, and the clinical decision being evaluated. Future studies should connect assay performance to patient benefit through comparison with existing care, clinically meaningful endpoints, and assessment of treatment burden and downstream investigations. This approach will help define where cfDNA testing can contribute meaningfully to breast cancer management.

Biomarker ResearchVol. 14(1)
Hong Kong Sanatorium and Hospital (HK), University of Hong Kong (HK)
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon